Cadrenal Therapeutics Inc
CVKD
Company Profile
Business description
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Contact
822 A1A North
Suite 306
Ponte VedraFL32082
USAT: +1 904 300-0701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,970.86 | 78.25 | 0.99% |
| DAX 40 | 21,504.92 | 93.39 | 0.44% |
| Dow JONES (US) | 44,565.07 | 408.34 | 0.92% |
| FTSE 100 | 8,536.57 | 28.63 | -0.33% |
| HKSE | 20,066.19 | 365.63 | 1.86% |
| NASDAQ | 20,053.68 | 44.34 | 0.22% |
| Nikkei 225 | 39,931.98 | 26.89 | -0.07% |
| NZX 50 Index | 13,024.70 | 35.38 | -0.27% |
| S&P 500 | 6,118.71 | 32.34 | 0.53% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,252.63 | 22.46 | 0.70% |